Ultrasound cyclo plasty in advanced glaucoma: Intermediate-term success, predictors for failure and complications

医学 青光眼 眼压 危险系数 比例危险模型 眼科 青光眼药物治疗 青光眼手术 外科 内科学 置信区间
作者
Faisal A. Almobarak,Ahmed Alrubean,Waleed K. Alsarhani,Abdullah Aljenaidel
出处
期刊:European Journal of Ophthalmology [SAGE]
被引量:1
标识
DOI:10.1177/11206721241235430
摘要

Purpose To report the intermediate-term success rate of ultrasound cyclo plasty (UCP), predictors for failure and complications in advanced glaucoma. Methods This study included patients with advanced glaucoma who underwent UCP. The main outcome measures were intraocular pressure (IOP), the number of antiglaucoma medications, and the presence of complications. Success was defined as an IOP reduction ≥30% and IOP between 6 mmHg and 18 mmHg with no vision-threatening complications. Cox proportional hazard regression analysis was performed to identify possible predictors for failure. Results We included 65 eyes of 58 patients in the study. The mean IOP and number of antiglaucoma medications decreased significantly from 27.60 ± 5.5 mmHg and 3.40 ± 0.9 at baseline to 17.80 ± 8.0 mmHg (35.51% reduction) and 2.43 ± 1.3 at 12 months and 17.10 ± 8.2 mmHg (38.04% reduction) and 2.41 ± 1.5 at 24 months, respectively ( p < 0.01 for both). The success rates were 66.2% (43/65) and 72.4% (21/29), while the failure rates were 33.8% (22/65) and 27.6% (8/29) at 12 and 24 months postoperatively, respectively. The cumulative probabilities of overall success were 67.7 ± 5.8% and 33.8 ± 5.9% at 12 and 24 months, respectively. High baseline IOP and history of old glaucoma surgery were associated with a higher risk for failure (Hazard ratio = 1.10 and 5.82, p = 0.03 and p < 0.01, respectively). The most common complications were anterior chamber reaction (18.5%) and cataract development/progression (15.4%). Two eyes (3.1%) developed phthisis bulbi. Conclusions Although UCP is effective in lowering IOP in eyes with advanced glaucoma, the intermediate-term success rates were moderate.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
lixoii发布了新的文献求助20
刚刚
豌豆射手发布了新的文献求助10
1秒前
科研通AI2S应助k7采纳,获得10
1秒前
wszldmn完成签到,获得积分10
1秒前
坚定的亦绿完成签到,获得积分10
2秒前
2秒前
yurh完成签到,获得积分10
2秒前
小朋友完成签到,获得积分10
3秒前
华仔应助小王采纳,获得10
3秒前
彭于晏应助乔乔采纳,获得10
3秒前
3秒前
1199完成签到,获得积分10
3秒前
3秒前
南瓜完成签到 ,获得积分10
4秒前
eric曾完成签到,获得积分10
5秒前
6秒前
6秒前
7秒前
韦威风完成签到,获得积分10
7秒前
请叫我风吹麦浪应助cc采纳,获得30
7秒前
所所应助Ll采纳,获得10
7秒前
阳光的道消完成签到,获得积分10
8秒前
8秒前
8秒前
豌豆射手完成签到,获得积分10
9秒前
9秒前
桑桑发布了新的文献求助10
9秒前
领导范儿应助幸福胡萝卜采纳,获得10
10秒前
明理的小甜瓜完成签到,获得积分10
11秒前
11秒前
33333完成签到,获得积分20
11秒前
11秒前
11秒前
756发布了新的文献求助10
11秒前
12秒前
科研通AI5应助GHOST采纳,获得10
12秒前
12秒前
罗实完成签到,获得积分10
13秒前
科研通AI2S应助k7采纳,获得10
13秒前
13秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Social media impact on athlete mental health: #RealityCheck 1020
Ensartinib (Ensacove) for Non-Small Cell Lung Cancer 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
Bacterial collagenases and their clinical applications 800
El viaje de una vida: Memorias de María Lecea 800
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3527742
求助须知:如何正确求助?哪些是违规求助? 3107867
关于积分的说明 9286956
捐赠科研通 2805612
什么是DOI,文献DOI怎么找? 1540026
邀请新用户注册赠送积分活动 716884
科研通“疑难数据库(出版商)”最低求助积分说明 709762